Last month, our Editor, Josh Hardman, attended the American Psychiatric Association’s (APA) five-day annual meeting in San Francisco. There, he took the temperature of a field that is struggling to make sense of its standing in American society, and that is now confronted with a class of potential therapeutics—psychedelics—that it can’t quite place. Over the course of the meeting…
